Endocrine Abstracts

Dopamine agonists (DAs) are usually used as first line treatment in prolactinomas. Some tumors do not normalize prolactin levels under treatment and demonstrate a more aggressive course. The mechanisms underlying this chemoresistance are poorly understood. Previous gene expression studies have focused on candidate genes such as the DA receptor 2 (DRD2) or the nerve growth factor (NGF), but transcriptome analyses comparing tumors resistant and responsive to DA are still lacking...

Introduction/Background: Adrenal incidentaloma is defined as an asymptomatic adrenal mass greater than 1 cm, discovered during imaging performed for another purpose1. The main goal when discovering such a tumor is to rule out a hormonally active lesion or a malignant condition. Radiological characteristics on non-contrast CT or MRI can help to determine if a lesion is benign. If the lesion nature remains indeterminate after these exams, it is recomm...

Introduction: Various tumours have a worse prognosis in male than in female. This is also true for lactotroph tumours. Indeed it is known that aggressive and malignant tumours, resistant to dopamine agonists, are more frequent in male than female and are associated to lower ESR1 expression.Objectives: Our aims are to study the genes differentially expressed and the chromosomic alterations in lactotroph tumours between male and female and their relationsh...